HIV clinical stages and lower extremity arterial disease among HIV infected outpatients in Burundi.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
29
08
2019
accepted:
30
03
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Chronic disease of people living with human immunodeficiency virus (HIV) infection are now approaching those of the general population. Previous, in vitro studies shown that HIV causes arterial injuries resulting in inflammation and atherosclerosis but direct relationship between HIV infection clinical stages and lower extremity arterial disease (LEAD) remain controversial. No study assessed, with an accurate method, both the prevalence of LEAD and the influence of HIV severity on LEAD in HIV outpatients in Central Africa. A cross-sectional study was conducted among 300 HIV-infected outpatients, aged ≥ 40 years in Bujumbura, Burundi. All patients underwent ankle-brachial index (ABI) measurement and LEAD was diagnosed by ABI ≤ 0.9. The prevalence of LEAD was 17.3% (CI 95% 13.2-22.1). The mean age was 49.6 ± 7.1 years. On multivariable analysis, factors associated with LEAD were hypertension (OR = 2.42; 95% CI 1.10-5.80), and stage IV HIV clinical infection (OR = 4.92, 95% CI 1.19-20.36). This is the first study performed on a large HIV population in Central Africa, reporting high LEAD prevalence. It underlines the influence of HIV infection on peripheral atherosclerosis at latest clinical stages and the need for LEAD screening in HIV-infected patients.
Identifiants
pubmed: 33859308
doi: 10.1038/s41598-021-87862-z
pii: 10.1038/s41598-021-87862-z
pmc: PMC8050048
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8296Références
J Am Coll Cardiol. 2006 Sep 19;48(6):1190-7
pubmed: 16979004
Vasc Med. 2003 Nov;8(4):237-42
pubmed: 15125483
Circulation. 1999 Aug 17;100(7):700-5
pubmed: 10449690
Int J STD AIDS. 2005 Oct;16(10):677-80
pubmed: 16212715
N Engl J Med. 2005 Jan 6;352(1):48-62
pubmed: 15635112
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
HIV Med. 2019 Jan;20(1):54-59
pubmed: 30160365
Atherosclerosis. 2019 Jul;286:121-127
pubmed: 31136913
Int Angiol. 2012 Jun;31(3):227-33
pubmed: 22634976
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
AIDS. 2009 Jun 1;23(9):1059-67
pubmed: 19390417
BMC Public Health. 2019 Aug 20;19(1):1143
pubmed: 31429736
Circulation. 2018 Jul 17;138(3):255-265
pubmed: 29535090
Am Heart J. 2002 Jun;143(6):961-5
pubmed: 12075249
Int J Cardiol. 2018 Sep 15;267:198-201
pubmed: 29859709
AIDS. 2005 Apr 29;19(7):641-52
pubmed: 15821390
Eur J Vasc Endovasc Surg. 2012 Aug;44(2):164-9
pubmed: 22705162
J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):506-12
pubmed: 12869840
Eur J Prev Cardiol. 2015 Nov;22(11):1462-72
pubmed: 25376847
Circulation. 2012 Dec 11;126(24):2890-909
pubmed: 23159553
Clin Infect Dis. 2007 Jun 15;44(12):1625-31
pubmed: 17516408
HIV Med. 2012 Sep;13(8):453-68
pubmed: 22413967
AIDS. 2010 May 15;24(8):1228-30
pubmed: 20400883
Enferm Infecc Microbiol Clin. 2011 Nov;29(9):672-8
pubmed: 21907462
J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):471-7
pubmed: 12154337
Lancet. 1999 Jun 19;353(9170):2093-9
pubmed: 10382692
Am J Prev Med. 2005 Dec;29(5 Suppl 1):42-9
pubmed: 16389125
Ann Intern Med. 2006 Sep 19;145(6):397-406
pubmed: 16983127
Vasc Health Risk Manag. 2018 Dec 06;14:401-408
pubmed: 30584314
AIDS. 2014 May 15;28(8):1181-91
pubmed: 24901259
Infect Dis (Lond). 2015;47(11):776-82
pubmed: 26114988
PLoS One. 2014 Dec 12;9(12):e113857
pubmed: 25503743